The National Institutes of Health has renewed funding for the Antibacterial Resistance Leadership Group (ARLG), which coordinates clinical research on antibacterial resistance, with up to $102.5 million over seven years.
As part of the new grant, ARLG will “support improved diagnostic tests for identifying antibiotic-resistant microbes,” NIH said in a statement.
The grant starts with $15 million in 2020, awarded by the National Institute for Allergy and Infectious Disease (NIAID) to co-principal investigators Vance Fowler of Duke University and Henry Chambers of the University of California, San Francisco.
“The renewal support from the NIAID will allow the ARLG to continue its collaborative work to advance science in antibacterial research, and to provide funding opportunities for the next generation of researchers dedicated to addressing this public health threat,” Fowler said in a statement.
Antibacterial resistance has emerged as a serious health issue in the United States — and in long-term care, in particular. A U.S. Centers for Disease Control and Prevention report published last year estimated that 35,000 people in the U.S. die each year due to infections from resistant bacteria. The CDC offers an extensive section on its website dedicated to improving antibiotic prescribing practices and reducing inappropriate use in nursing homes.
From the February 2020 Issue of McKnight's Long-Term Care News
